Abstract
Drug allergy refers to a hypersensitivity reaction for which either an IgE or T-cell-mediated mechanism is demonstrated. The recognition of the drug by B and T cells is influenced by variants of HLA genes. The genetic factors involved in IgE-mediated mechanisms have been studied mainly in β-lactam reactions, and they appear to be related to human leukocyte antigen presentation (HLA A2 and DRw52), TNFA – 308G > A, class switching to IgE by B cells (variants of IL-13 and of IL-4RA), and expression of IgE receptors on target cells (variant of the FcηRIβ gene). Delayed Tcell- mediated reactions are also associated with HLA alleles. Studies have reported an association of HLA-B*1502 and HLA-B*5801 in patients with the Stevens-Johnson syndrome or toxic epidermal necrolysis provoked by carbamazepine, as well as of HLA-B*5701 with abacavir hypersensitivity. HLA-B*5701 seems to be a strong predictor in whites, but not in Hispanics or Africans. Carbamazepine hypersensitivity is also influenced by gene variants of cytochrome P450 enzymes on the generation of reactive metabolites, while CYP2C9*2 and CYP2C9*3 polymorphisms influence the bioactivation of sulfamethoxazole in prohapten. Pharmacogenetic studies on aspirin hypersensitivity have identified distinct types of predictors, such as HLA genotypes, a polymorphism in the promoter of the FcηRIα gene, and variants in genes of enzymes from the arachidonic acid pathway. In the future, identification of genetic predictors will benefit from genomewide association studies that also take ethnic differences into account. Ideally, predictors will help to prevent adverse reactions, as suggested by a recent study on the effectiveness of prospective HLA-B* 5701 screening to prevent hypersensitivity reactions to abacavir in HIV patients.
Keywords: Pharmacogenetics, gene polymorphism, drug hypersensitivity, drug allergy, β-lactams, aspirin, sulfamethoxazole, abacavir
Current Pharmaceutical Design
Title: Pharmacogenetic Determinants of Immediate and Delayed Reactions of Drug Hypersensitivity
Volume: 14 Issue: 27
Author(s): J. L. Gueant, R. M. Gueant-Rodriguez, I. Aimone Gastin, J. A. Cornejo-Garcia, M. Viola, A. Barbaud, P. M. Mertes, M. Blanca and A. Romano
Affiliation:
Keywords: Pharmacogenetics, gene polymorphism, drug hypersensitivity, drug allergy, β-lactams, aspirin, sulfamethoxazole, abacavir
Abstract: Drug allergy refers to a hypersensitivity reaction for which either an IgE or T-cell-mediated mechanism is demonstrated. The recognition of the drug by B and T cells is influenced by variants of HLA genes. The genetic factors involved in IgE-mediated mechanisms have been studied mainly in β-lactam reactions, and they appear to be related to human leukocyte antigen presentation (HLA A2 and DRw52), TNFA – 308G > A, class switching to IgE by B cells (variants of IL-13 and of IL-4RA), and expression of IgE receptors on target cells (variant of the FcηRIβ gene). Delayed Tcell- mediated reactions are also associated with HLA alleles. Studies have reported an association of HLA-B*1502 and HLA-B*5801 in patients with the Stevens-Johnson syndrome or toxic epidermal necrolysis provoked by carbamazepine, as well as of HLA-B*5701 with abacavir hypersensitivity. HLA-B*5701 seems to be a strong predictor in whites, but not in Hispanics or Africans. Carbamazepine hypersensitivity is also influenced by gene variants of cytochrome P450 enzymes on the generation of reactive metabolites, while CYP2C9*2 and CYP2C9*3 polymorphisms influence the bioactivation of sulfamethoxazole in prohapten. Pharmacogenetic studies on aspirin hypersensitivity have identified distinct types of predictors, such as HLA genotypes, a polymorphism in the promoter of the FcηRIα gene, and variants in genes of enzymes from the arachidonic acid pathway. In the future, identification of genetic predictors will benefit from genomewide association studies that also take ethnic differences into account. Ideally, predictors will help to prevent adverse reactions, as suggested by a recent study on the effectiveness of prospective HLA-B* 5701 screening to prevent hypersensitivity reactions to abacavir in HIV patients.
Export Options
About this article
Cite this article as:
Gueant L. J., Gueant-Rodriguez M. R., Gastin Aimone I., Cornejo-Garcia A. J., Viola M., Barbaud A., Mertes M. P., Blanca M. and Romano A., Pharmacogenetic Determinants of Immediate and Delayed Reactions of Drug Hypersensitivity, Current Pharmaceutical Design 2008; 14 (27) . https://dx.doi.org/10.2174/138161208786369795
DOI https://dx.doi.org/10.2174/138161208786369795 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Skin Tests in the Diagnosis of Drug Hypersensitivity Reactions
Current Pharmaceutical Design Medication-Induced Acute Abdominal Pain: Evaluation with CT Imaging
Current Medical Imaging New Antihypertensive Drugs Under Development
Current Medicinal Chemistry Hypersensitivity Reactions to Neuromuscular Blocking Agents
Current Pharmaceutical Design Design, Development and Optimization of Ramipril Solid Lipid Nanoparticles Using Solvent Emulsification and Evaporation Method
Nanoscience & Nanotechnology-Asia Contact Allergy to Topical Corticosteroids: Update and Review on Cross- Sensitization
Recent Patents on Inflammation & Allergy Drug Discovery Inflammation and Coagulation in Urticaria and Angioedema
Current Vascular Pharmacology The Guanylyl Cyclase Inhibition by MB as Vasoplegic Circulatory Shock Therapeutical Target
Current Drug Targets Basophil Activation Test with Indomethacin to Assess Hypersensitivity to Non-Steroidal Anti-Inflammatory Drugs: A Preliminary Study
Inflammation & Allergy - Drug Targets (Discontinued) Potassium Channel Openers and Improvement of Toxic Stress: Do they have Role in the Management of Inflammatory Bowel Disease?
Inflammation & Allergy - Drug Targets (Discontinued) Blood Coagulation as an Intrinsic Pathway for Proinflammation: A Mini Review
Inflammation & Allergy - Drug Targets (Discontinued) Treatment of Hereditary Angioedema: Current Perspectives
Recent Patents on Inflammation & Allergy Drug Discovery Cardiovascular Effects of Hypoglycemic Agents in Diabetes Mellitus
Current Drug Safety Complement and Microglia in the Neuropathogenesis of HIV Infection: Pro- and Anti-Inflammatory Aspects
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry A Brief Review of Cardiovascular Diseases, Associated Risk Factors and Current Treatment Regimes
Current Pharmaceutical Design Aliskiren: A Novel Renin Inhibitor for Hypertension
Current Drug Therapy Drug Development and the Importance of Ethnicity: Lessons from Heart Failure Management and Implications for Hypertension
Current Pharmaceutical Design Acute and Long-Term Effects of Cannabis Use: A Review
Current Pharmaceutical Design Immediate Hypersensitivity Reactions to Penicillins and Other Betalactams
Current Pharmaceutical Design Downregulation of Membrane-bound Angiotensin Converting Enzyme 2 (ACE2) Receptor has a Pivotal Role in COVID-19 Immunopathology
Current Drug Targets